Mentice AB (FRA:MN2) 6-Month Price Index: 1.07 (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MN2 Mentice AB FRA:MN2
75 GF Score
Price €1.28
GF Value €1.93
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Mentice AB 6-Month Price Index?

Mentice AB FRA:MN2 +7.82% 75 6-Month Price Index is 1.07 as of Sep. 21, 2026. GuruFocus rates FRA:MN2 with a GF Score™ of 75/100 and a GF Value™ of €1.93 (Significantly Undervalued). The stock has 2 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-21), Mentice AB's 6-Month Price Index is 1.07.

Mentice AB  (FRA:MN2) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Mentice AB 6-Month Price Index Related Terms

FRA:MN2 vs ABT, SYK, MDT: 6-Month Price Index Comparison

For the Medical Devices subindustry, Mentice AB's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FRA:MN2
75GF Score
Mentice AB FRA:MN2
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mentice AB  (FRA:MN2) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.07 mean?
Mentice AB (FRA:MN2) has a 6-Month Price Index of 1.07 as of Sep. 21, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Mentice AB and its competitors.
Is Mentice AB's 6-Month Price Index too high?
Mentice AB's current 6-Month Price Index is 1.07. Overall, Mentice AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's 6-Month Price Index compare to ABT and SYK?
Mentice AB's 6-Month Price Index of 1.07 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Medical Devices & Instruments company?
A good 6-Month Price Index depends on the Medical Devices & Instruments industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Mentice AB and its competitors. Mentice AB's current 6-Month Price Index is 1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (FRA:MN2) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.93, compared to a current price of €1.28 — trading 33.7% below its estimated fair value. The current 6-Month Price Index is 1.07. Mentice AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Mentice AB (FRA:MN2), the current 6-Month Price Index is 1.07 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mentice AB (FRA:MN2) Overvalued in 2026?

Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued. The current stock price of €1.28 is trading 33.7% below its estimated GF Value™ of €1.93. GuruFocus considers Mentice AB to be Significantly Undervalued.

Key valuation signals for FRA:MN2:

  • 6-Month Price Index: 1.07
  • GF Value™: €1.93 vs. price of €1.28 (33.7% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the FRA:MN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mentice AB Business Description

Other Exchanges MNTC:Sweden
Address Odinsgatan 10, Gothenburg, SWE, 411 03
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
75GF Score

Get the complete analysis for FRA:MN2

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.28
Price
€1.93
GF Value